Indication & Dosage |
|
|
Oral |
MANAGEMENT OF PSYCHIATRIC CONDITIONS |
Adult:
25 mg tid; may be given as a single 75 mg dose at night. Maintenance: 25-100 mg tid increased to ≥ 1 g daily as required in psychotic patients. |
|
Oral |
MANAGEMENT OF PSYCHIATRIC CONDITIONS |
Child:
|
|
Any Route |
MANAGEMENT OF PSYCHIATRIC CONDITIONS |
Adult:
|
|
Any Route |
MANAGEMENT OF PSYCHIATRIC CONDITIONS |
Adult:
|
|
Any Route |
ALLEVIATE INTRACTABLE HICCUP |
Adult:
|
|
Any Route |
ALLEVIATE INTRACTABLE HICCUP |
Child:
|
|
Any Route |
CONTROL OF NAUSEA AND VOMITING ASSOCIATED WITH SURGERY |
Adult:
|
|
Any Route |
CONTROL OF NAUSEA AND VOMITING ASSOCIATED WITH SURGERY |
Child:
|
|
|
|
Administration |
May be taken with or without food. (May be taken w/ meals to reduce GI discomfort.) |
|
|
Precautions |
Parkinson's disease; CV disease; renal or hepatic impairment; cerebrovascular and respiratoty disease; jaundice; DM; hypothyroidism; paralytic ileus; prostatic hyperplasia or urinary retention; epilepsy or history of seizures; myasthenia gravis; pregnancy; elderly (especially with dementia), and debilitated patients. Avoid direct sunlight. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Tardive dyskinesia (on long-term therapy). Involuntary movements of extremities may also occur. Dry mouth, constipation, urinary retention, mydriasis, agitation, insomnia, depression and convulsions; postural hypotension, ECG changes. Allergic skin reaction, amenorrhoea, gynaecomastia, weight gain. Hyperglycaemia and raised serum cholesterol. |
|
|
Adverse Drug Reactions |
Agranulocytosis. Instantaneous deaths associated with ventricular tachyarrhythmias. Marked elevation of body temperature with heat stroke. Neuroleptic malignant syndrome, extrapyramidal dysfunction. |
|
|
Interactions |
Additive depressant effect with sedatives, hypnotics, antihistamines, general anaesthetics, opiates and alcohol. Potentiation of anticholinergic effects of antiparkinson agents and TCAs may lead to an anticholinergic crisis. Additive orthostatic hypotensive effect in combination with MAOIs. Reverses antihypertensive effect of guanethidine, methyldopa and clonidine. |
|
|